News
SNY
50.35
+0.64%
0.32
BRIEF-Regeneron Completes Purchase Of Sanofi's Stake In Libtayo (Cemiplimab)
BRIEF-Regeneron Completes Purchase Of Sanofi's Stake In Libtayo (Cemiplimab)
Reuters · 18h ago
Regeneron Completes Acquisition of Sanofi's Rights to Cancer Drug
MT Newswires · 22h ago
Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold
Sanofi stock crumbled Thursday after the FDA slapped two of its final-phase studies with a hold, citing safety concerns.
Investor's Business Daily · 1d ago
Sanofi's Drug Trials for Multiple Sclerosis, Myasthenia Gravis Put on Partial Hold by FDA; US Enrollment Paused
MT Newswires · 1d ago
Billionaire Ray Dalio is Shorting These 10 European Stocks
In this article, we discuss the 10 European stocks billionaire Ray Dalio is shorting. You can skip our analysis of the economic environment and go directly to Billionaire Ray Dalio is Shorting These 5 European Stocks. Billionaire Ray Dalio’s Bridgewater As...
Insider Monkey · 1d ago
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.
Zacks · 1d ago
Why Sanofi Shares Are Falling Today
The FDA has placed Sanofi SA's (NASDAQ: SNY) Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold. New enrollment in the U.S. is paused, and participants in the U.S. who have been in the trial for fewer than ...
Benzinga · 1d ago
Sanofi tolebrutinib trials in MS/myasthenia gravis put on partial hold by FDA after cases of liver damage
The U.S. Food and Drug Administration (FDA) placed phase 3 studies of Sanofi's (NASDAQ:<a href="...
Seekingalpha · 1d ago
BRIEF-Sanofi: Patient Enrollment Of Phase III Tolebrutinib Trials Paused In U.S.
BRIEF-Sanofi: Patient Enrollment Of Phase III Tolebrutinib Trials Paused In U.S.
Reuters · 1d ago
Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients
Benzinga · 2d ago
Sanofi to cut out-of-pocket insulin costs to $35 for uninsured Americans
Sanofi (NASDAQ:SNY) (<a href="https://seekingalpha.com/symbol/SNYNF?utm_med...
Seekingalpha · 2d ago
Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.
Zacks · 3d ago
Sanofi Nexviadyme for Pompe disease gets approval in EU
The European Commission (EC) granted marketing authorization to Sanofi's (NASDAQ:SNY) enzyme replacement therapy (ERT) Nexviadyme for the long-term treatment of late-onset and infantile-onset Pompe disease (PD). PD is a rare genetic disorder
Seekingalpha · 3d ago
Sanofi enzyme replacement therapy Xenpozyme gets approval in EU for rare disorder
Sanofi said the European Commission (EC) approved its enzyme replacement therapy Xenpozyme to treat non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in children and adult patients with ASMD
Seekingalpha · 3d ago
Sanofi Wins European Commission Approvals for Enzyme Replacement Therapies
MT Newswires · 3d ago
BRIEF-Sanofi Announces Xenpozyme Approved By European Commission
BRIEF-Sanofi Announces Xenpozyme Approved By European Commission
Reuters · 4d ago
Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease Approved for the treatment of the full spectrum of both late-onset Pompe disease and infantile-onset Pompe diseaseFirs...
GlobeNewswire · 4d ago
Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD Paris, June 28, 2022. The European Commission (EC) has approved Xenpozyme® (olipudase alfa) as the first and only enzyme replacement therapy for the treatment ...
GlobeNewswire · 4d ago
Sanofi: Information concerning the total number of voting rights and shares – May 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation ...
GlobeNewswire · 4d ago
Investors are Watching These 10 Biotech Stocks
In this article, we discuss the 10 biotech stocks that investors are watching. If you want to read about some more biotech stocks, go directly to Investors are Watching These 5 Biotech Stocks. The stock market plunge in the past few weeks because of soarin...
Insider Monkey · 4d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.